1. Home
  2. KNOP vs CHRS Comparison

KNOP vs CHRS Comparison

Compare KNOP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KNOT Offshore Partners LP

KNOP

KNOT Offshore Partners LP

N/A

Current Price

$11.23

Market Cap

355.2M

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.34

Market Cap

177.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KNOP
CHRS
Founded
2013
2010
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
355.2M
177.7M
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
KNOP
CHRS
Price
$11.23
$1.34
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
42.7K
1.0M
Earning Date
05-19-2026
05-07-2026
Dividend Yield
1.86%
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.51
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
$9.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.00
$1.09
52 Week High
$11.78
$2.62

Technical Indicators

Market Signals
Indicator
KNOP
CHRS
Relative Strength Index (RSI) 59.31 49.09
Support Level $10.18 $1.29
Resistance Level $11.67 $1.49
Average True Range (ATR) 0.39 0.07
MACD 0.03 -0.00
Stochastic Oscillator 59.09 30.56

Price Performance

Historical Comparison
KNOP
CHRS

About KNOP KNOT Offshore Partners LP

KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: